Targeting RBP7 inhibits HCC cells proliferation via activation of p38 MAPK pathway, supporting that RBP7 could serve as a promising prognostic biomarker and potential therapeutic target in HCC. The gene discussed is RBP7; the disease is hepatocellular carcinoma.